Symbols / CGEN
CGEN Chart
About
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 166.62M |
| Enterprise Value | 82.42M | Income | -27.62M | Sales | 6.90M |
| Book/sh | 0.47 | Cash/sh | 0.92 | Dividend Yield | — |
| Payout | 0.00% | Employees | 74 | IPO | — |
| P/E | — | Forward P/E | -5.42 | PEG | — |
| P/S | 24.14 | P/B | 3.77 | P/C | — |
| EV/EBITDA | -2.60 | EV/Sales | 11.94 | Quick Ratio | 4.38 |
| Current Ratio | 4.38 | Debt/Eq | 6.72 | LT Debt/Eq | — |
| EPS (ttm) | -0.30 | EPS next Y | -0.33 | EPS Growth | — |
| Revenue Growth | -89.00% | Earnings | 2026-03-02 | ROA | -18.18% |
| ROE | -52.95% | ROIC | — | Gross Margin | 7.43% |
| Oper. Margin | -4.17% | Profit Margin | 0.00% | Shs Outstand | 93.54M |
| Shs Float | 91.63M | Short Float | 1.08% | Short Ratio | 1.73 |
| Short Interest | — | 52W High | 2.38 | 52W Low | 1.13 |
| Beta | 2.91 | Avg Volume | 408.64K | Volume | 202.29K |
| Target Price | $5.80 | Recom | None | Prev Close | $1.71 |
| Price | $1.77 | Change | 3.51% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.80
Mean price target
2. Current target
$1.77
Latest analyst target
3. DCF / Fair value
$5.80
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$1.77
Low
$4.00
High
$13.00
Mean
$5.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-07 | init | HC Wainwright & Co. | — → Buy | $4 |
| 2024-05-21 | main | Truist Securities | Buy → Buy | $4 |
| 2024-03-08 | main | Truist Securities | Buy → Buy | $5 |
| 2023-12-19 | main | Stifel | Buy → Buy | $4 |
| 2023-08-23 | reit | Truist Securities | Buy → Buy | $4 |
| 2023-08-07 | reit | EF Hutton | Buy → Buy | $13 |
| 2023-06-06 | reit | EF Hutton | — → Buy | $13 |
| 2023-05-26 | reit | EF Hutton | Buy → Buy | $13 |
| 2023-05-24 | reit | EF Hutton | Buy → Buy | $13 |
| 2023-05-16 | main | Oppenheimer | Outperform → Outperform | $7 |
| 2023-02-28 | reit | Oppenheimer | — → Outperform | $8 |
| 2023-02-08 | down | Jefferies | Hold → Underperform | $1 |
| 2023-01-05 | init | EF Hutton | — → Buy | $13 |
| 2022-11-15 | main | Oppenheimer | — → Outperform | $8 |
| 2022-08-23 | main | Truist Securities | — → Buy | $4 |
| 2022-08-08 | main | JMP Securities | — → Market Outperform | $4 |
| 2022-08-08 | main | Oppenheimer | — → Outperform | $12 |
| 2022-08-05 | down | Jefferies | Buy → Hold | $2 |
| 2022-02-25 | main | Oppenheimer | — → Outperform | $14 |
| 2022-02-25 | main | SVB Leerink | — → Outperform | $9 |
- Cancer immunotherapy firm Compugen to stream talks from two investor conferences - Stock Titan hu, 19 Feb 2026 12
- Compugen Stock: Runway Into 2027 But Expensive (NASDAQ:CGEN) - Seeking Alpha Mon, 27 Oct 2025 07
- There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise - simplywall.st ue, 07 Oct 2025 07
- Cancer immunotherapy royalty deal brings biotech up to $90M in funding - Stock Titan Wed, 17 Dec 2025 08
- Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance Wed, 06 Aug 2025 07
- New Analyst Forecast: $CGEN Given $4 Price Target - Quiver Quantitative Wed, 07 Jan 2026 08
- HC Wainwright & Co. Initiates Coverage of Compugen (CGEN) with Buy Recommendation - Nasdaq Wed, 07 Jan 2026 08
- Compugen Secures $90 Million in a Strategic Royalty Monetization Deal with AstraZeneca - TipRanks Wed, 17 Dec 2025 08
- Compugen stock soars on $65 million AstraZeneca royalty deal By Investing.com - Investing.com Nigeria Wed, 17 Dec 2025 08
- Compugen rises on royalty deal with AstraZeneca (CGEN:NASDAQ) - Seeking Alpha Wed, 17 Dec 2025 08
- Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation - simplywall.st hu, 02 Oct 2025 07
- 30-year healthcare strategist joins Compugen cancer board - Stock Titan hu, 12 Feb 2026 08
- Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts - Yahoo Finance Sun, 23 Mar 2025 07
- Compugen Presents Promising COM701 Analysis at ESMO 2025 - TipRanks ue, 14 Oct 2025 07
- Need To Know: Analysts Just Made A Substantial Cut To Their Compugen Ltd. (NASDAQ:CGEN) Estimates - Yahoo Finance Sat, 09 Aug 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -4.60K | -460.00 | 75.44K | 0.00 |
| TaxRateForCalcs | 0.23 | 0.23 | 0.23 | 0.00 |
| NormalizedEBITDA | -14.38M | -12.51M | -35.22M | -34.62M |
| TotalUnusualItems | -20.00K | -2.00K | 328.00K | 2.00K |
| TotalUnusualItemsExcludingGoodwill | -20.00K | -2.00K | 328.00K | 2.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.23M | -18.75M | -33.69M | -34.20M |
| ReconciledDepreciation | 486.00K | 476.00K | 482.00K | 461.00K |
| ReconciledCostOfRevenue | 7.93M | 2.00M | 975.00K | 680.00K |
| EBITDA | -14.40M | -12.52M | -34.89M | -34.61M |
| EBIT | -14.89M | -12.99M | -35.37M | -35.07M |
| NetInterestIncome | 5.20M | 3.21M | 1.41M | 869.00K |
| InterestExpense | 27.00K | 25.00K | ||
| InterestIncome | 3.49M | 2.96M | 1.44M | 894.00K |
| NormalizedIncome | -14.22M | -18.75M | -33.95M | -34.20M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -14.23M | -18.75M | -33.69M | -34.20M |
| TotalExpenses | 42.76M | 46.45M | 42.87M | 41.07M |
| TotalOperatingIncomeAsReported | -14.89M | -12.99M | -35.37M | -35.07M |
| DilutedAverageShares | 89.53M | 87.63M | 86.56M | 84.20M |
| BasicAverageShares | 89.53M | 87.63M | 86.56M | 84.20M |
| DilutedEPS | -0.16 | -0.21 | -0.39 | -0.41 |
| BasicEPS | -0.16 | -0.21 | -0.39 | -0.41 |
| DilutedNIAvailtoComStockholders | -14.23M | -18.75M | -33.69M | -34.20M |
| NetIncomeCommonStockholders | -14.23M | -18.75M | -33.69M | -34.20M |
| NetIncome | -14.23M | -18.75M | -33.69M | -34.20M |
| NetIncomeIncludingNoncontrollingInterests | -14.23M | -18.75M | -33.69M | -34.20M |
| NetIncomeContinuousOperations | -14.23M | -18.75M | -33.69M | -34.20M |
| TaxProvision | 4.52M | 8.97M | 58.00K | 0.00 |
| PretaxIncome | -9.71M | -9.78M | -33.64M | -34.20M |
| OtherIncomeExpense | -20.00K | -2.00K | 328.00K | 2.00K |
| SpecialIncomeCharges | 0.00 | -7.00K | -12.00K | 3.00K |
| GainOnSaleOfPPE | 0.00 | -7.00K | -12.00K | 3.00K |
| GainOnSaleOfSecurity | -20.00K | 5.00K | 340.00K | -1.00K |
| NetNonOperatingInterestIncomeExpense | 5.20M | 3.21M | 1.41M | 869.00K |
| TotalOtherFinanceCost | -1.71M | -250.00K | 27.00K | 25.00K |
| InterestExpenseNonOperating | 27.00K | 25.00K | ||
| InterestIncomeNonOperating | 3.49M | 2.96M | 1.44M | 894.00K |
| OperatingIncome | -14.89M | -12.99M | -35.37M | -35.07M |
| OperatingExpense | 34.83M | 44.45M | 41.90M | 40.39M |
| ResearchAndDevelopment | 24.81M | 34.47M | 30.65M | 28.69M |
| SellingGeneralAndAdministration | 10.02M | 9.97M | 11.25M | 11.70M |
| SellingAndMarketingExpense | 576.00K | 244.00K | 932.00K | 842.00K |
| GeneralAndAdministrativeExpense | 9.44M | 9.73M | 10.32M | 10.86M |
| OtherGandA | 9.44M | 9.73M | 10.32M | 10.86M |
| GrossProfit | 19.93M | 31.45M | 6.53M | 5.32M |
| CostOfRevenue | 7.93M | 2.00M | 975.00K | 680.00K |
| TotalRevenue | 27.86M | 33.46M | 7.50M | 6.00M |
| OperatingRevenue | 27.86M | 33.46M | 7.50M | 6.00M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 89.54M | 89.24M | 86.62M | 86.43M |
| ShareIssued | 89.54M | 89.24M | 86.62M | 86.43M |
| TotalDebt | 2.91M | 1.35M | 1.93M | 2.75M |
| TangibleBookValue | 54.91M | 65.56M | 77.68M | 106.69M |
| InvestedCapital | 54.91M | 65.56M | 77.68M | 106.69M |
| WorkingCapital | 85.84M | 88.31M | 74.21M | 106.13M |
| NetTangibleAssets | 54.91M | 65.56M | 77.68M | 106.69M |
| CapitalLeaseObligations | 2.91M | 1.35M | 1.93M | 2.75M |
| CommonStockEquity | 54.91M | 65.56M | 77.68M | 106.69M |
| TotalCapitalization | 54.91M | 65.56M | 77.68M | 106.69M |
| TotalEquityGrossMinorityInterest | 54.91M | 65.56M | 77.68M | 106.69M |
| StockholdersEquity | 54.91M | 65.56M | 77.68M | 106.69M |
| GainsLossesNotAffectingRetainedEarnings | 11.00K | 2.00K | 0.00 | |
| OtherEquityAdjustments | 11.00K | 2.00K | ||
| RetainedEarnings | -488.76M | -474.53M | -455.77M | -422.08M |
| AdditionalPaidInCapital | 543.41M | 539.84M | 533.21M | 528.53M |
| CapitalStock | 248.00K | 247.00K | 240.00K | 239.00K |
| CommonStock | 248.00K | 247.00K | 240.00K | 239.00K |
| TotalLiabilitiesNetMinorityInterest | 60.08M | 55.77M | 16.50M | 25.47M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 39.92M | 29.51M | 4.58M | 8.37M |
| EmployeeBenefits | 3.41M | 3.40M | 3.27M | 3.68M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 3.41M | 3.40M | 3.27M | 3.68M |
| NonCurrentDeferredLiabilities | 34.05M | 25.39M | 0.00 | 2.71M |
| NonCurrentDeferredRevenue | 34.05M | 25.39M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 2.46M | 719.00K | 1.31M | 1.98M |
| LongTermCapitalLeaseObligation | 2.46M | 719.00K | 1.31M | 1.98M |
| CurrentLiabilities | 20.16M | 26.27M | 11.92M | 17.10M |
| CurrentDeferredLiabilities | 9.63M | 11.15M | 325.00K | 3.63M |
| CurrentDeferredRevenue | 9.63M | 11.15M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 448.00K | 632.00K | 613.00K | 768.00K |
| CurrentCapitalLeaseObligation | 448.00K | 632.00K | 613.00K | 768.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.07M | 3.12M | 2.81M | 3.30M |
| PayablesAndAccruedExpenses | 7.01M | 11.36M | 8.17M | 9.40M |
| CurrentAccruedExpenses | 5.17M | 7.86M | 6.40M | 4.78M |
| Payables | 1.84M | 3.50M | 1.77M | 4.62M |
| AccountsPayable | 1.84M | 3.50M | 1.77M | 4.62M |
| TotalAssets | 115.00M | 121.33M | 94.18M | 132.16M |
| TotalNonCurrentAssets | 9.00M | 6.75M | 8.05M | 8.94M |
| OtherNonCurrentAssets | 343.00K | |||
| DefinedPensionBenefit | 3.07M | 2.98M | 2.79M | 3.12M |
| NonCurrentPrepaidAssets | 1.89M | 1.23M | 1.90M | 1.91M |
| NetPPE | 3.69M | 2.54M | 3.36M | 3.90M |
| AccumulatedDepreciation | -5.75M | -5.36M | -6.23M | -5.84M |
| GrossPPE | 9.44M | 7.90M | 9.59M | 9.75M |
| Leases | 2.31M | 2.31M | 2.31M | 2.32M |
| OtherProperties | 2.84M | 1.33M | 1.83M | 2.25M |
| MachineryFurnitureEquipment | 4.29M | 4.26M | 5.45M | 5.18M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 106.00M | 114.58M | 86.12M | 123.22M |
| RestrictedCash | 0.00 | 365.00K | 362.00K | 713.00K |
| PrepaidAssets | 2.47M | 2.21M | 2.10M | 5.27M |
| Receivables | 269.00K | 61.32M | 317.00K | 188.00K |
| OtherReceivables | 269.00K | 318.00K | 317.00K | 188.00K |
| AccountsReceivable | 0.00 | 61.00M | 0.00 | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 103.25M | 50.69M | 83.35M | 117.05M |
| OtherShortTermInvestments | 85.03M | 36.80M | 72.29M | 109.25M |
| CashAndCashEquivalents | 18.23M | 13.89M | 11.06M | 7.80M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 49.49M | -36.06M | -34.60M | -22.98M |
| IssuanceOfCapitalStock | 544.00K | 3.08M | 0.00 | 14.96M |
| CapitalExpenditure | -118.00K | -172.00K | -487.00K | -292.00K |
| InterestPaidSupplementalData | 3.05M | 852.00K | 1.36M | |
| EndCashPosition | 18.23M | 14.26M | 11.42M | 8.51M |
| BeginningCashPosition | 14.26M | 11.42M | 8.51M | 7.81M |
| EffectOfExchangeRateChanges | 68.00K | 129.00K | -393.00K | -59.00K |
| ChangesInCash | 3.91M | 2.71M | 3.30M | 763.00K |
| FinancingCashFlow | 554.00K | 3.08M | 353.00K | 16.84M |
| CashFlowFromContinuingFinancingActivities | 554.00K | 3.08M | 353.00K | 16.84M |
| ProceedsFromStockOptionExercised | 10.00K | 0.00 | 353.00K | 1.88M |
| NetCommonStockIssuance | 544.00K | 3.08M | 0.00 | 14.96M |
| CommonStockIssuance | 544.00K | 3.08M | 0.00 | 14.96M |
| InvestingCashFlow | -46.25M | 35.51M | 37.06M | 6.62M |
| CashFlowFromContinuingInvestingActivities | -46.25M | 35.51M | 37.06M | 6.62M |
| NetOtherInvestingChanges | -330.00K | |||
| NetInvestmentPurchaseAndSale | -45.80M | 35.68M | 37.55M | 6.91M |
| SaleOfInvestment | 113.95M | 89.39M | 114.44M | 136.85M |
| PurchaseOfInvestment | -159.75M | -53.70M | -76.90M | -129.94M |
| NetPPEPurchaseAndSale | -117.00K | -172.00K | -485.00K | -289.00K |
| SaleOfPPE | 1.00K | 0.00 | 2.00K | 3.00K |
| PurchaseOfPPE | -118.00K | -172.00K | -487.00K | -292.00K |
| OperatingCashFlow | 49.60M | -35.89M | -34.11M | -22.69M |
| CashFlowFromContinuingOperatingActivities | 49.60M | -35.89M | -34.11M | -22.69M |
| ChangeInWorkingCapital | 62.05M | -20.71M | -5.55M | 6.82M |
| ChangeInOtherWorkingCapital | 7.14M | 36.22M | -6.02M | 3.71M |
| ChangeInOtherCurrentLiabilities | -503.00K | -645.00K | -1.06M | -416.00K |
| ChangeInOtherCurrentAssets | 550.00K | 568.00K | 658.00K | 525.00K |
| ChangeInPayablesAndAccruedExpense | -4.41M | 3.51M | -1.60M | 3.37M |
| ChangeInPayable | -4.41M | 3.51M | -1.60M | 3.27M |
| ChangeInAccountPayable | -4.41M | 3.51M | -1.60M | 3.37M |
| ChangeInPrepaidAssets | -655.00K | 666.00K | 12.00K | -31.00K |
| ChangeInReceivables | 59.93M | -61.02M | 2.46M | -333.00K |
| ChangesInAccountReceivables | 61.00M | -61.00M | 0.00 | 2.00M |
| OtherNonCashItems | -1.57M | -280.00K | ||
| StockBasedCompensation | 3.02M | 3.55M | 4.33M | 4.28M |
| DepreciationAmortizationDepletion | 486.00K | 476.00K | 482.00K | 461.00K |
| DepreciationAndAmortization | 486.00K | 476.00K | 482.00K | 461.00K |
| Depreciation | 486.00K | 476.00K | 482.00K | 461.00K |
| OperatingGainsLosses | -149.00K | -172.00K | 324.00K | -45.00K |
| PensionAndEmployeeBenefitExpense | -81.00K | -50.00K | -81.00K | -101.00K |
| NetForeignCurrencyExchangeGainLoss | -68.00K | -129.00K | 393.00K | 59.00K |
| GainLossOnSaleOfPPE | 0.00 | 7.00K | 12.00K | -3.00K |
| NetIncomeFromContinuingOperations | -14.23M | -18.75M | -33.69M | -34.20M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CGEN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|